ContraFect (NASDAQ:CFRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of ContraFect (NASDAQ:CFRX – Get Rating) in a research report issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, SVB Leerink dropped their price objective on shares of ContraFect from $14.00 to $9.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 16th.

Shares of NASDAQ CFRX opened at $3.89 on Thursday. The company has a market cap of $153.01 million, a PE ratio of -6.95 and a beta of 0.50. The business’s 50 day moving average price is $3.66 and its two-hundred day moving average price is $3.29. ContraFect has a twelve month low of $2.11 and a twelve month high of $4.76.

ContraFect (NASDAQ:CFRX – Get Rating) last released its quarterly earnings data on Thursday, March 24th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.13. Equities analysts forecast that ContraFect will post -1.19 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Wedmont Private Capital acquired a new position in ContraFect in the fourth quarter valued at about $25,000. Moody Lynn & Lieberson LLC purchased a new stake in shares of ContraFect during the 4th quarter worth $26,000. Mayflower Financial Advisors LLC acquired a new position in shares of ContraFect during the 4th quarter worth $26,000. Envestnet Asset Management Inc. purchased a new stake in ContraFect during the 1st quarter worth about $41,000. Finally, Acadian Asset Management LLC purchased a new stake in ContraFect in the 4th quarter valued at about $46,000. 59.39% of the stock is owned by institutional investors and hedge funds.

About ContraFect (Get Rating)

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia.

Further Reading